Among Seniors, a Declining Interest in Boosters - The New York Times (nytimes.com)

...

Although Americans over 65 remain the demographic most likely to have received the original series of vaccinations, at 92 percent, their interest in keeping their vaccinations up-to-date is steadily declining, data from the C.D.C. shows. To date, about 71 percent have received the first recommended booster, but only about 44 percent have received the second.

Younger people have also been less likely to receive boosters than the original vaccinations, and only about one-third of people of all ages have received any booster, The New York Times vaccine tracker indicates. But seniors, who constitute 16 percent of the population, are more vulnerable to the virus’s effects, accounting for three-quarters of the nation’s 1.1 million deaths.

“From the beginning, older people have felt the virus was more of a threat to their safety and health and have been among the earliest adopters of the vaccine and the first round of boosters,” said Mollyann Brodie, the executive director of public opinion at Kaiser Family Foundation, which has been tracking vaccination rates and attitudes.

Covid-19 vaccine study links side effects with greater antibody response | CNN

People who reported experiencing side effects to the Pfizer/BioNTech and Moderna Covid-19 vaccines such as fever, chills or muscle pain tended to have a greater antibody response following vaccination, according to new research.

Having such symptoms after vaccination is associated with greater antibody responses compared with having only pain or rash at the injection site or no symptoms at all, suggests the paper published Friday in the journal JAMA Network Open.

Ivermectin: Still on a Losing Streak as COVID-19 Treatment | MedPage Today

WASHINGTON -- There were no differences in relief from mild-to-moderate COVID-19 symptoms for patients on ivermectin versus placebo, according to the ongoing ACTIV-6 trial.

Among >1,000 vaccinated and unvaccinated patients, the median time to recovery was 12 days for those in the ivermectin group and 13 days in the placebo group, reported Matthew McCarthy, MD, of Weill Cornell Medicine in New York City, at IDWeek.

As a result, the hazard ratio for improvement in time to recovery was 1.07 (95% credible interval 0.96-1.17, posterior P=0.91), McCarthy and colleagues stated in JAMA, where the results were simultaneously published.

...

Uganda applies well-honed lessons to new Ebola outbreak (nbcnews.com)

...the East African country — lauded for its coronavirus response, which was built around engaging the community and training health officials — is drawing lessons from the first Ebola outbreak in 2004.

ALSO SEE: Uganda reports worrisome increase in Ebola cases in capital

Six people who tested positive for monkeypox have died, health departments confirm | CNN

....

The two Chicagoans who died after testing positive for monkeypox had multiple other health conditions, including weakened immune systems, according to the Chicago Department of Health (CDPH).

“Though the number of new MPV cases has declined substantially since summer, this is a stark reminder that MPV is dangerous and can cause serious illness, and in very rare cases, even death,” said CDPH Commissioner Dr. Allison Arwady.

...

Biden to get updated COVID vaccine, urge Americans to follow suit | Reuters

 (Reuters) - U.S. President Joe Biden will get his updated COVID-19 vaccine on Tuesday and urge more Americans to get the latest shot, White House spokesman Kevin Munoz said on Sunday.

Only 20 million people in the United States have received an updated COVID vaccine through last week. White House spokeswoman Karine Jean-Pierre said on Thursday it was not enough.

...

Omicron subvariants pose a new threat to people with immune deficiencies (nbcnews.com)

New versions of the omicron virus show resistance to the antibody drugs many need for extra protection against Covid.

---

People with compromised immune systems face a new winter of discontent as the ever-mutating omicron virus threatens to outrun the preventive monoclonal antibody cocktail that hundreds of thousands of them have relied upon for extra protection against Covid.

The main COVID symptoms have changed, research shows | The Hill

 ... like all viruses, the primary symptoms associated with COVID have changed and can vary based on your vaccination status, according to a new list released last week.

...

Researchers have found that for participants in all three groups — fully vaccinated, those who received just one dose, and unvaccinated — four of the five most commonly reported symptoms are the same: sore throat, runny nose, persistent cough, and headache.

Their prevalences across the groups, however, vary, as does the fifth symptom.

For those who are vaccinated, a blocked nose is the third-most frequently reported symptom. Among the partially vaccinated, it’s sneezing, and the unvaccinated, fever.

Below are the symptoms most commonly reported among the three groups, ranked in order of how often they are reported.  ...

A ‘Tripledemic’? Flu and Other Infections Return as Covid Cases Rise - The New York Times (nytimes.com)

For more than two years, shuttered schools and offices, social distancing and masks granted Americans a reprieve from flu and most other respiratory infections. This winter is likely to be different.

With few to no restrictions in place and travel and socializing back in full swing, an expected winter rise in Covid cases appears poised to collide with a resurgent influenza season, causing a “twindemic” — or even a “tripledemic,” with a third pathogen, respiratory syncytial virus, or R.S.V., in the mix.

Cases of BQ.1, BQ.1.1 COVID variants double in U.S. as Europe warns of rise U.S. regulators estimated BQ.1 and closely related BQ.1.1 accounted for 16.6% of COVID variants in the country, nearly doubling from last week, as Europe expects them to become dominant in a month. Manas Mishra,Khushi Mandowara Reuters

...

Analysis: Falling demand for COVID boosters puts price hikes on the table With most Americans delaying or skipping new COVID-19 booster shots, analysts and investors are now predicting far fewer will be given each year, pushing the number of shots well below annual flu vaccinations. Michael Erman Reuters

...

Pfizer says COVID-19 vaccine will cost $110-$130 per dose Pfizer will charge $110 to $130 for a dose of its COVID-19 vaccine once the U.S. government stops buying the shots, but the drugmaker says it expects many people will continue receiving it for free. AP NEWS

...

Pfizer executives said the commercial pricing for adult doses could start early next year, depending on when the government phases out its program of buying and distributing the shots.

A common respiratory virus is spreading at unusually high levels, overwhelming children's hospitals. Here's what parents need to know | CNN There's now an "unprecedented" rise in RSV cases among children in the US, some doctors say. Several children's hospitals told CNN that they've been "overwhelmed" with patients at a time of the year when it's unusual to have a surge of RSV patients. Jen Christensen,Raenu Charles CNN

...

Cholera outbreak hits Syrian refugees sheltering in camps in Lebanon Syrian refugees in displacement camps are falling victim to a cholera outbreak in Lebanon, already suffering from an economic meltdown that has slashed access to clean water and strained hospitals. Maya Gebeily Reuters

...